Biological, as opposed to classic antipsoriatic drug or apremilast, treatment mitigates the risk of death and cardiovascular disease in psoriasisResearch in context

Biological, as opposed to classic antipsoriatic drug or apremilast, treatment mitigates the risk of death and cardiovascular disease in psoriasisResearch in context

Summary: Background: Cardiovascular comorbidity increases morbidity and mortality in psoriasis. Systemic treatments, particularly biologics, are effective in alleviating skin and joint inflammation. Conversely, the impact of systemic therapy on cardiovascular disease risk and mortality in psoriasis...

Full description

Saved in:
Bibliographic Details
Main Authors: Khalaf Kridin, Katja Bieber, Artem Vorobyev, Eva Lotta Moderegger, Henning Olbrich, Marlene A. Ludwig, Bernard Gershater, Gema Hernandez, Henner Zirpel, Diamant Thaci, Ralf J. Ludwig
Format: Article
Language:English
Published: Elsevier 2025-01-01
Series:EBioMedicine
Subjects:
Psoriasis
Mortality
Major adverse cardiac events (MACE)
Comorbidity
Cardiovascular
TriNetX
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396424005218
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2352396424005218

Similar Items